Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06145269 |
| Other study ID # |
Recanalization rate(acute DVT) |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
Early Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2023 |
| Est. completion date |
June 1, 2025 |
Study information
| Verified date |
November 2023 |
| Source |
Assiut University |
| Contact |
Amr Yaseen, bachelor |
| Phone |
01020398137 |
| Email |
amryaseen1996[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Rporting and evaluation of the rate of recanalization of acute DVT of the lower limb at one
year follow-up comparing the results of using NOACs vs. conventional treatment.
Description:
Deep vein thrombosis (DVT) is an important cause of disability and mortality in our society .
The incidence of DVT significantly increases with age, being more prevalent in women than men
. The location of DVT is also an important factor to be studied because of its association
with pulmonary embolism and development of post-thrombotic syndrome (PTS) , Currently, duplex
ultrasound scanning (DUS) is the method of choice for diagnosis of DVT because it is
non-invasive, provides real-time imaging, and has high sensitivity and specificity especially
for detection of proximal DVT .
The new oral anticoagulants (NOACs), are poised to replace warfarin for treatment of the
majority of patients with venous thromboembolism (VTE), With a rapid onset of action and the
capacity to be administered in fixed doses without routine coagulation monitoring, NOACs have
been shown to be noninferior to conventional anticoagulant therapy for prevention of
recurrence with less bleeding.
Most studies have reported that more advantages than disadvantages for NOACs when compared
with VKAs, with the most important advantages of NOACs including safety issues (ie, a lower
incidence of major bleeding), convenience of use, minor drug and food interactions, a wide
therapeutic window, and no need for laboratory monitoring. Nonetheless, there are some
conditions for which VKAs remain the drug of choice.
